Noara Therapeutics is developing a novel class of therapeutic RNAs using its MITREN platform, which applies machine intelligence to design, create, and screen RNA molecules that are immunosilent, active, and exceptionally stable. This approach addresses the instability of mRNAs and the immunogenicity and manufacturing challenges of circular and self-amplifying RNAs. The platform enables high-throughput screening to identify optimized RNA candidates for therapeutic development.
Funding
Funding not disclosed
Founders
Product
Problem
Current RNA therapeutic modalities face significant limitations: mRNAs are inherently unstable, while circular and self-amplifying RNAs tend to be immunogenic and difficult to manufacture. These drawbacks confine existing RNA therapeutics primarily to vaccines for infectious diseases and select cancers, limiting their broader therapeutic potential.
Solution
Noara Therapeutics has developed MITREN, a proprietary platform for Machine Intelligence-guided Therapeutic RNA Engineering. MITREN enables the design, creation, and high-throughput screening of a novel RNA modality that is immunosilent, active, and exceptionally stable. By leveraging machine intelligence, the platform systematically optimizes RNA sequences for enhanced stability and reduced immunogenicity, overcoming the key barriers of current approaches. This enables the development of therapeutic RNAs with broader applicability beyond vaccines, potentially unlocking new treatment options for a wide range of diseases.
Target Audience
Primary customers are biotechnology and pharmaceutical companies seeking to develop RNA-based therapeutics for a broader range of diseases beyond infectious disease vaccines, particularly those requiring stable and immunosilent RNA molecules.
Features
- MITREN platform integrates machine intelligence to guide the design and engineering of novel RNA therapeutics
- High-throughput screening capabilities allow rapid evaluation and optimization of RNA candidates
- Novel RNA modality is engineered to be immunosilent, avoiding unwanted immune responses
- Molecules are designed for exceptional stability, addressing the inherent instability of conventional mRNAs
- Platform enables creation of RNA therapeutics with activity profiles suitable for applications beyond infectious disease vaccines